via Georgia State University
Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.
The group led by Dr. Richard Plemper, Distinguished University Professor at Georgia State, originally discovered that the drug is potent against influenza viruses.
“This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission,” said Plemper. “MK-4482/EIDD-2801 could be game-changing.”
Interrupting widespread community transmission of SARS-CoV-2 until mass vaccination is available is paramount to managing COVID-19 and mitigating the catastrophic consequences of the pandemic.
Because the drug can be taken by mouth, treatment can be started early for a potentially three-fold benefit: inhibit patients’ progress to severe disease, shorten the infectious phase to ease the emotional and socioeconomic toll of prolonged patient isolation and rapidly silence local outbreaks.
“We noted early on that MK-4482/EIDD-2801 has broad-spectrum activity against respiratory RNA viruses and that treating infected animals by mouth with the drug lowers the amount of shed viral particles by several orders of magnitude, dramatically reducing transmission,” said Plemper. “These properties made MK-4482/EIDD/2801 a powerful candidate for pharmacologic control of COVID-19.”
In the study published in Nature Microbiology, Plemper’s team repurposed MK-4482/EIDD-2801 against SARS-CoV-2 and used a ferret model to test the effect of the drug on halting virus spread.
“We believe ferrets are a relevant transmission model because they readily spread SARS-CoV-2, but mostly do not develop severe disease, which closely resembles SARS-CoV-2 spread in young adults,” said Dr. Robert Cox, a postdoctoral fellow in the Plemper group and a co-lead author of the study.
The researchers infected ferrets with SARS-CoV-2 and initiated treatment with MK-4482/EIDD-2801 when the animals started to shed virus from the nose.
“When we co-housed those infected and then treated source animals with untreated contact ferrets in the same cage, none of the contacts became infected,” said Josef Wolf, a doctoral student in the Plemper lab and co-lead author of the study. By comparison, all contacts of source ferrets that had received placebo became infected.
If these ferret-based data translate to humans, COVID-19 patients treated with the drug could become non-infectious within 24 hours after the beginning of treatment.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- How Molnupiravir Moved to the Head of the 'COVID Pill' Packon April 28, 2021 at 3:36 pm
Molnupiravir is a small molecule drug being investigated as an oral antiviral with broad spectrum activity against RNA viruses such as SARS-CoV-2. The drug acts as a ribonucleoside analog for an ...
- Cipla ties up with MSD to make, distribute investigational drug molnupiravir in Indiaon April 28, 2021 at 10:57 am
The MSD is developing molnupiravir in collaboration with Ridgeback Biotherapeutics. This agreement is a part of Cipla's efforts to enhance global access to treatment for patients affected by the ...
- MSD in talks with Medicines Patent Pool for additional licenses for molnupiraviron April 27, 2021 at 11:48 pm
MSD entered into a voluntary licensing agreement with five Indian drug makers including Sun Pharma, Cipla, Dr. Reddys, Emcure and Hetero for molnupiravir, an experimental drug that is currently tested ...
- Hetero, the Hyderabad-based generic pharmaceutical company, to manufacture the anti-viral drug Molnupiravir in Indiaon April 27, 2021 at 8:58 am
In what will come as a ray of hope as India battles the growing number of COVID-19 infections, Hyderabad-based generic pharmaceutical company Hetero has entered into a non-exclusive voluntary licensi ...
- MSD ties up with 5 Indian pharma majors for supply of oral COVID-19 drug Molnupiraviron April 27, 2021 at 5:10 am
MSD has signed agreements with Cipla Ltd., Dr. Reddy’s Laboratories, Emcure Pharmaceuticals Ltd., Hetero Labs Ltd. and Sun Pharmaceutical Industries Ltd ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Furin cleavage site crucial in SARS-CoV-2 for viral transmission in ferrets, finds studyon April 30, 2021 at 9:34 am
Researchers based at Imperial College London, UK, have recently highlighted the effects of these deleterious CS mutations through a ferret animal model, demonstrating that furin cleavage sites are a ...
- Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccineon April 30, 2021 at 8:26 am
A single dose of vaccine boosts protection against SARS-CoV-2 coronavirus variants, but only in those with previous COVID-19, a study has found.
- Human to animal transmission of SARS-CoV-2 in households is commonon April 29, 2021 at 8:14 pm
Coronaviruses are seen in multiple mammalian species. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, is said to have passed to humans from ...
- The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferretson April 27, 2021 at 3:31 pm
Efficient transmission of SARS-CoV-2 among infected ferrets requires a functional furin cleavage site in the SARS-CoV-2 spike protein.
- Scientists find evidence of human-to-cat COVID-19 transmissionon April 27, 2021 at 4:27 am
The novel coronavirus has been well documented in cats big and small across the world, and now a U.K. study shows evidence of human-to-cat transmission of SARS-CoV-2 in two cases.